OVID — Ovid Therapeutics Share News
0.000.00%
Last trade - 00:00- $462.86m
- $345.64m
- $7.25m
Ovid Therapeutics Q2 revenue beats estimates
Brief: Ovid Therapeutics Q2 EPS USD -0.08
Ovid Therapeutics Inc. expected to post a loss of 11 cents a share - Earnings Preview
Brief: Ovid Therapeutics Appoints Leading Physician-Scientist And Biotech Innovator Anna Greka, M.D., Ph.D., To Board Of Directors
Ovid Therapeutics Q1 net loss widens as R&D spending rises
Brief: Ovid Therapeutics Q1 EPS USD -0.12
U.S. STOCKS ON THE MOVE-Vertex Pharma, U.S. Energy Corp, SoFi Technologies
U.S. STOCKS ON THE MOVE-InspireMD, MiniMed, SoFi Technologies
U.S. STOCKS ON THE MOVE-Tencent, Air Products, Protagonist
U.S. STOCKS ON THE MOVE-Lululemon, Swarmer, DocuSign
Brief: Ovid Therapeutics Announces New Ov329 Data And Indication Expansion, Phase 1 Clearance For Ov4071, And Reports Fourth Quarter And Full Year 2025 Financial Results
Brief: Ovid Therapeutics Announces Pricing Of $60 Million Private Placement
Ovid Therapeutics rises as epilepsy drug shows clean safety
Brief: Ovid Therapeutics Announces Phase 1 Results For Ov350
Ovid Therapeutics Q3 revenue slightly beats expectations
U.S. STOCKS ON THE MOVE-Occidental Petroleum , GameStop, Alphabet
Ovid Therapeutics jumps after seizure treatment shows promise in trial
Brief: Ovid Therapeutics Regains Compliance With Nasdaq Listing Rule - SEC Filing
Ovid Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary